 | | Vol. 13.02 – 4 February, 2025 |
| |
|
|
| Scientists analyzed tumor tissue samples from 205 cervical cancer patients undergoing radiotherapy, scRNA-seq data from 42,159 cells of eight patients, and bulk RNA-sequencing data from 187 radiotherapy-treated patients.
[Molecular Cancer] |
|
|
|
 | | PUBLICATIONSListed by the impact factor of the journal |
|
|
|
| An integrative, multi-omic approach was applied to independent datasets to characterize diffuse large B-cell lymphoma (DLBCL) immune environments and define their association with tumor cell-intrinsic genomic alterations and outcomes to CD19-directed CAR T-cell and CD20 x CD3 bispecific antibody therapies.
[Blood] |
|
|
|
| Investigators presented substudy results on short-term repeat intramuscular cabotegravir + rilpivirine long-acting thigh injections in participants with ≥3 years of experience with gluteal administration during the ATLAS–2M study.
[Clinical Infectious Diseases] |
|
|
|
| Researchers applied imaging mass cytometry to a balanced cohort of lung adenocarcinoma and lung squamous cell carcinoma patients, matched for clinical factors such as age, sex, and smoking history, to analyze 204 histopathology images of tumours from 102 individuals with non-small cell lung cancer.
[Nature Communications] |
|
|
|
| Using engineered dendritic cells with surface-bound photosensitizers, the authors generated reactive oxygen species at immune synapses, leading to the targeted death of antigen-specific T cells in close proximity.
[Angewandte Chemie-International Edition] |
|
|
|
| This randomized, Phase II SQUINT trial assessed the efficacy of nivolumab plus ipilimumab versus platinum-based chemotherapy plus nivolumab and to identify clinically available biomarkers of response to immunotherapy in patients with advanced or metastatic lung squamous cell carcinoma.
[Clinical Cancer Research] |
|
|
|
| Researchers identified a robust poly ADP ribosyl polymerase 14 (PARP14) catalytic inhibitor gene signature and evaluated its association with patient survival.They investigated immune and tumor cell adaptations to PARP14 inhibition combined with programmed cell death 1 blockade.
[Journal For Immunotherapy of Cancer] |
|
|
|
| The clinical trial evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma.
[Journal for Immunotherapy of Cancer] |
|
|
|
| Scientists demonstrated that the cellular protein M-Sec promoted the transmission of human T cell leukemia virus type 1 (HTLV-1) in vitro and in vivo.
[PLOS Pathogens] |
|
|
|
|
| The authors discuss recent advances in versatile human tonsil/adenoid tissue-based ex vivo immune organoid cultures as well as related cancer and autoimmunity-focused experimental setups.
[EMBO Molecular Medicine] |
|
|
|
|
| Allogene Therapeutics, Inc. announced that the US FDA has cleared its Investigational New Drug (IND) application for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR T product.
[Allogene Therapeutics, Inc.] |
|
|
|
|
| March 2-7, 2025
Ventura, California, United States |
|
|
|
|
|
| | University of California, San Diego – San Diego, California, United States |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Cedars-Sinai Medical Center – Los Angeles, California, United States |
|
|
|
| | Biogen – San Francisco, California, United States |
|
|
|
| | Technical University of Munich – Munich, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
